ストックスクリーナーアプリを入手
42.02
1.94%
0.80
アフターアワーズ：
43.00
0.98
+2.33%
前日終値:
$41.22
開ける：
$40.1
24時間の取引高:
726.90K
Relative Volume:
0.75
時価総額：
$3.44B
収益：
-
当期純損益:
$-153.72M
株価収益率:
-75.04
EPS:
-0.56
ネットキャッシュフロー:
$-103.81M
1週間 パフォーマンス:
+1.45%
1か月 パフォーマンス:
+8.16%
6か月 パフォーマンス:
+186.04%
1年 パフォーマンス:
+153.44%
1日の値動き範囲:
$40.10
$42.86
1週間の範囲:
$39.67
$43.73
52週間の値動き範囲:
$11.39
$43.73
Verona Pharma Plc Adr Stock (VRNA) Company Profile
名前
Verona Pharma Plc Adr
セクター
電話
011-44-0-2032834200
住所
3 MORE LONDON RIVERSIDE, LONDON
VRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
42.02 | 3.44B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-03 | 開始されました | Wells Fargo | Overweight |
| 2023-05-22 | 再開されました | Jefferies | Buy |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-08-26 | 開始されました | Piper Sandler | Overweight |
| 2021-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-25 | 開始されました | Jefferies | Buy |
| 2020-08-10 | 開始されました | Canaccord Genuity | Buy |
| 2019-04-18 | 開始されました | BTIG Research | Buy |
すべてを表示
Verona Pharma Plc Adr (VRNA) 最新ニュース
Verona Pharma CFO Mark Hahn sells shares worth $4.4 million - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $4.36 million - Investing.com
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 - Investing.com India
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 By Investing.com - Investing.com South Africa
Verona Pharma CEO David Zaccardelli sells shares worth $627,233 - Investing.com
Verona Pharma CFO sells shares totaling $12,000 - Investing.com India
Verona Pharma's chief medical officer sells $1.18 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $8,000 - Investing.com
Verona Pharma director David Ebsworth buys $88,800 in shares - Investing.com India
Verona Pharma director Christina Ackermann acquires $198,385 in shares - Investing.com
Verona Pharma CFO Mark Hahn sells shares worth $568,386 - Investing.com
Verona Pharma CEO David Zaccardelli sells $618,657 in shares - Investing.com
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre By Investing.com - Investing.com Nigeria
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre - Investing.com India
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday - Investing.com Nigeria
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday By Investing.com - Investing.com South Africa
Verona Pharma ADR earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Verona Pharma CFO Mark Hahn sells shares worth $632,760 - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $633,895 - Investing.com India
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
5 Biotech Stocks Likely To Outperform As Industry Prospects Look Bright - Barchart
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million - Investing.com India
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
Market Insights: Verona Pharma Plc ADR (VRNA)’s Notable Drop of -0.55, Closing at 34.07 - The Dwinnex
Verona Pharma Plc ADR [VRNA] Insider Activity: An Update for Investors - Knox Daily
Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily
Verona Pharma Plc ADR (VRNA) stock: A year of ups and downs - US Post News
VRNA Shares Experience Decline in Value - Knox Daily
Financial Metrics Exploration: Understanding Verona Pharma Plc ADR (VRNA) Through Ratios - The Dwinnex
A stock that deserves closer examination: Verona Pharma Plc ADR (VRNA) - US Post News
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Wells Fargo gives an Overweight recommendation for Verona Pharma Plc ADR (VRNA) - Knox Daily
Verona Pharma Plc ADR’s (NASDAQ: VRNA) Stock Forecast: Increase To $38 In A Year - Stocks Register
Prepare Yourself for Liftoff: Verona Pharma Plc ADR (VRNA) - SETE News
Verona Pharma Plc ADR [VRNA] stock for 2,254,320 USD was sold by ZACCARDELLI DAVID - Knox Daily
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - Yahoo Finance
Cactus Inc [WHD] Records 50-Day SMA of $59.34 - Knox Daily
Verona Pharma stock soars to all-time high of $30.76 By Investing.com - Investing.com South Africa
Piper Sandler maintains Overweight rating on Verona Pharma shares By Investing.com - Investing.com South Africa
Sea Limited Sponsored ADR (SE) Stock Moves -0.17%: What You Should Know - Yahoo Finance
Verona Pharma stock soars to all-time high of $30.76 - Investing.com
VRNA’s Stock Market Adventure: 58.43% YTD Growth Amidst Volatility - The InvestChronicle
Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) Moves 6.2% Higher: Will This Strength Last? - Yahoo Finance
Tesla and Nvidia Lead Afternoon Market Cap Stock Movers on Thursday - Investing.com
MINISO Group Holding Limited Unsponsored ADR (MNSO) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Verona Pharma Plc ADR (VRNA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Investing in Verona Pharma Plc ADR (VRNA) might be a great opportunity, but the stock is a bit overvalued - US Post News
Verona Pharma Plc Adr (VRNA) 財務データ
収益
当期純利益
現金流量
EPS
Verona Pharma Plc Adr (VRNA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ZACCARDELLI DAVID | President and CEO |
Dec 06 '24 |
Sale |
5.01 |
162,800 |
815,400 |
14,204,752 |
| ZACCARDELLI DAVID | President and CEO |
Dec 04 '24 |
Sale |
5.00 |
67,608 |
338,162 |
15,007,816 |
| Hahn Mark W | Chief Financial Officer |
Dec 05 '24 |
Sale |
5.01 |
640,048 |
3,204,144 |
13,477,464 |
| Hahn Mark W | Chief Financial Officer |
Dec 06 '24 |
Sale |
5.01 |
183,728 |
920,312 |
13,293,736 |
| Hahn Mark W | Chief Financial Officer |
Dec 04 '24 |
Sale |
5.00 |
58,184 |
290,996 |
14,117,512 |
| Hahn Mark W | Chief Financial Officer |
Nov 29 '24 |
Sale |
5.01 |
98,704 |
494,142 |
14,177,296 |
| Hahn Mark W | Chief Financial Officer |
Nov 27 '24 |
Sale |
5.00 |
12,936 |
64,680 |
14,276,000 |
| Hahn Mark W | Chief Financial Officer |
Dec 02 '24 |
Sale |
5.00 |
1,600 |
8,000 |
14,175,696 |
| ZACCARDELLI DAVID | President and CEO |
Nov 29 '24 |
Sale |
5.01 |
98,888 |
495,033 |
15,078,624 |
| ZACCARDELLI DAVID | President and CEO |
Nov 27 '24 |
Sale |
5.00 |
23,240 |
116,200 |
15,177,512 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):